Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. The Company is focused on new product candidates and platforms to expand its pipeline based on a deep understanding of immunotherapies and its license agreements with University of California San Diego.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-26	US$0.000000	-	31
26-08-24	US$0.000000	-	11
26-08-21	US$0.000000	-	1
26-08-20	US$0.000000	-	10
26-08-18	US$0.000000	-	16

Delayed Quote OTC Markets

More quotes

Delayed OTC Markets 15:29:56 2026-08-13 EDT			5-day change	1st Jan Change
0.0610 ^USD	-87.80%		0.00%	-80.39%

08-14	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-20	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	442K 379K 355K 325K 612K 42.19M 614K 4.2M 1.64M 21.26M 1.66M 1.62M 70.38M	P/E 2024	-5.39x	P/E 2025	-3.11x
Enterprise Value	2.1M 1.81M 1.69M 1.55M 2.92M 201M 2.92M 20.02M 7.83M 101M 7.9M 7.73M 335M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	11.32%	Yield 2024 *	-	Yield 2025	-

08-14	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-20	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Mosaic ImmunoEngineering, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-19	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-19	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-20	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-15	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-04-14	Mosaic ImmunoEngineering, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-11-19	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-14	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-07-25	Mosaic ImmunoEngineering, Inc. Announces Resignation of Carlton Johnson from the Board, the Audit Committee and Compensation Committee	CI
24-05-14	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

24-04-29	Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.	AQ
24-03-28	Mosaic ImmunoEngineering : Termination of Material Agreement - Form 8-K	PU
23-05-03	MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers (form 8-K)	AQ
23-03-02	MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
22-11-01	MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

Mosaic ImmunoEngineering, Inc. Stock

Stocks

CPMV

US61945M1018

Biotechnology & Medical Research

Valuation : Mosaic ImmunoEngineering, Inc.

Chart: Mosaic ImmunoEngineering, Inc.

Latest news : Mosaic ImmunoEngineering, Inc.

Press Releases : Mosaic ImmunoEngineering, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Mosaic ImmunoEngineering, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-87.80%
Current month	+1.67%
1 month	-90.95%
3 months	-91.71%
6 months	-91.33%
Current year	-80.39%

1 month	0.05	0.67
Current year	0.05	0.75
1 year	0.05	1.05
3 years	0.05	1.13
5 years	0.05	3
10 years	0.05	9.22

Date	Insider	Type	Main position	% Market Cap.
2/18/22	Robert Garnick	Others	Founder	0%
2/18/22	Steven King	Others	Chief Executive Officer	0%
2/18/22	Robert Baffi	Others	Director	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MOSAIC IMMUNOENGINEERING, INC.	-87.80%	0.00%	-93.20%	-89.83%	442K
LONZA GROUP AG	+0.10%	+0.44%	+2.80%	+23.74%	50.96B
REVOLUTION MEDICINES, INC.	+2.56%	+4.28%	+480.42%	+584.41%	46.18B
BEONE MEDICINES AG	-0.63%	+0.96%	+24.18%	+84.42%	42.73B
IQVIA HOLDINGS INC.	+0.83%	+2.98%	+39.66%	+18.89%	43.04B
CELLTRION, INC.	-2.27%	-3.02%	+14.22%	+51.50%	33.48B
MEDPACE HOLDINGS, INC.	-0.48%	+0.58%	+30.14%	+135.49%	17.28B
ASCENDIS PHARMA A/S	-0.59%	-2.26%	-	-	16.43B
EUROFINS SCIENTIFIC SE	+0.25%	+0.25%	+12.03%	+28.88%	14.73B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.36%	+2.93%	+84.28%	+50.94%	14.09B
Average	-8.59%	+1.20%	+66.06%	+98.72%	27.89B
Weighted average by Cap.	+0.36%	+1.16%	+104.49%	+144.10%

	2024	2025
Net sales	-	-
Net income	-922K -791K -741K -678K -1.28M -88.06M -1.28M -8.77M -3.43M -44.38M -3.46M -3.39M -147M	-688K -590K -553K -506K -954K -65.69M -956K -6.55M -2.56M -33.11M -2.58M -2.53M -110M
Net Debt	1.48M 1.27M 1.19M 1.09M 2.05M 141M 2.05M 14.06M 5.5M 71.12M 5.55M 5.43M 235M	1.66M 1.43M 1.34M 1.22M 2.3M 159M 2.31M 15.82M 6.18M 80.01M 6.24M 6.11M 265M